Zepbound for Sleep Apnea: The First Drug Approved for OSA
Zepbound has an FDA-approved indication for moderate to severe obstructive sleep apnea in adults with obesity. It is part of a sleep-care plan, not permission to stop CPAP independently.
GLP-1 Brands & Reviews
- #1
CoreAge Rx
Editorial score: 9.8/10
CoreAge Rx offers clinician-reviewed compounded weight care. Compare the annual offer from $79/month for semaglutide or $129/month for tirzepatide with the full payment, dispensing details and refund conditions.
Semaglutide from $79/mo · Tirzepatide from $129/mo
Published
- Online prescribing and pharmacy fulfillment
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #2
SuperHealthy Rx
Editorial score: 9.6/10
SuperHealthy Rx advertises compounded semaglutide at $85/month and tirzepatide at $135/month, with a provider visit and shipping included. Confirm the current offer, billing term and state eligibility.
Semaglutide: $85/month advertised · Tirzepatide: $135/month advertised
Published
- Online prescribing and pharmacy fulfillment
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #3
Likeness Rx
Editorial score: 9.4/10
Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.
Semaglutide from $79/month · Tirzepatide from $129/month
Published
- Online prescribing and pharmacy fulfillment
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #4
Henry Meds
Editorial score: 9.3/10
Henry describes cash-pay plans bundling visits, medicine, supplies and ongoing care. Its multi-month cancellation terms can differ from its monthly plans.
Complete current quote needed
Published
- Telehealth and weight care
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #5
Hims
Editorial score: 9.1/10
Hims currently publishes a weight-loss membership with approved product options and medication billed separately. Older compounded-only descriptions do not capture its current offer.
Membership, medicine extra
Published
- Telehealth and weight care
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
Publisher preference scores. Comparison method and commercial relationships.
At a glance
- Confirm the diagnosis and severity with the sleep clinician.
- The approved indication is specific to Zepbound and the studied population.
- Reassess symptoms and objective sleep measures before changing established therapy.
What the sleep-apnea approval covers
FDA’s December 2024 announcement describes Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, alongside reduced-calorie eating and physical activity. It does not establish a treatment for every sleep disorder or for everyone who snores.
The trials evaluated sleep-apnea outcomes, not just weight. An advertisement for compounded tirzepatide should not be treated as an approval for that product or as proof of the same outcomes.
Sources: FDA: Zepbound for obstructive sleep apneaZepbound prescribing information
Keep the current treatment discussion connected
A sleep specialist can explain whether medication complements positive airway pressure and when a repeat study is needed. Do not discontinue CPAP or another prescribed device simply because weight decreases or daytime sleepiness seems better.
Sleepiness, snoring and wearable readings cannot by themselves establish that sleep apnea has resolved.
Sources: FDA: Zepbound for obstructive sleep apneaZepbound prescribing information
Document the relevant indication
Ask the insurer and prescriber about the required diagnostic study, severity documentation and product-specific authorization criteria. Coverage for a sleep-apnea indication can differ from a weight-management benefit.
Sources: FDA: Zepbound for obstructive sleep apneaZepbound prescribing information
Sources and review boundaries
Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.
- FDA: Zepbound for obstructive sleep apneaMedical or regulatory source · Source reviewed ·
- Zepbound prescribing informationMedical or regulatory source · Source reviewed ·
Related Articles
Understanding Anxiety: Types, Symptoms, and Treatment Options
Mental wellbeing deserves its own care plan. Neither an online intake nor a medication headline can replace an assessment of persistent anxiety, mood changes or disordered eating.
Choosing GLP-1 Options for Fatty Liver Disease
Fatty liver, MASH and advanced liver disease are different clinical situations. Wegovy’s current label includes a specific MASH indication, so an older statement that every GLP-1 use is investigational needs correction.
Choosing GLP-1 for Cardiovascular Risk Reduction
Cardiovascular claims should name the studied product, population and outcome. Wegovy has a specific cardiovascular risk-reduction indication; it is not a blanket claim for all GLP-1s.
Choosing GLP-1 Options for Men
For men, compare the clinical indication and support for sleep apnea, cardiometabolic risk and everyday strength. Gender-focused branding does not prove that one medicine works better.
Choosing GLP-1 Options During Menopause
During menopause, obesity treatment and care for hot flashes, sleep or genitourinary symptoms can overlap without being the same treatment. Ask how these needs will be assessed separately.
Choosing GLP-1 Options for PCOS
GLP-1 treatment may be considered for a coexisting approved indication in someone with PCOS. It is not an approved cure for PCOS or a substitute for reproductive-health care.
By Chief Medical Correspondent. Original publication date was not recorded. Updates are recorded when content changes.